Bayer AG, a prominent player in the bio-tech market, has shown consistent resilience amid numerous challenges. Over several years, the company has faced major losses, but is now charting a remarkable 40% rebound. It recently got a 'Buy' rating upgrade from Wall Street Zen. The pharma and litigation upsides of the stock have also caught the eyes of Goldman Sachs who bumped their rating up to 'Buy'. Increased demand for Bayer's cancer drugs has boosted its shares. On another front, the U.S. Supreme Court is seeking opinions in the glyphosate case that the company is entangled in. Despite racking up significant losses in Q4 of last year, their growth view starting FY26 has investors optimistic. The results from Bayer's Q1 outperformed estimates, with the downside of losses coming from its Crop Science Unit. Bayer's shares experienced a slump after it was ordered to pay more than $2B in the latest Roundup case. However, nod for possible capital raise over legal woes and approval for hormone-free treatment for women in the UK are likely to bring in new momentum. Despite these ups and downs, it's apparent that there's a potential for investors to yield great dividends in the long run.
BAYER Stocks News Analytics from Wed, 25 Sep 2024 07:00:00 GMT to Tue, 22 Jul 2025 12:58:00 GMT -
Rating 5
- Innovation -2
- Information 3
- Rumor -5
